What's breaking now, across thousands of outlets.
Akeso and Summit Therapeutics claimed a key win over Keytruda at the start of September, and are now spelling out that survival data. They hope it will add to the trove of results supporting the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Key PointsJoby Aviation would sport a $64 billion market cap if it grew tenfold from today.
When the energetic planet Mars enters its sign of debilitation ( neecha ), Cancer, from September 18 to November 12, 2026, a 56-day phase of financial shifts, market volatility, and global realignment…
On paper, a tenfold gain isn't far-fetched, but can Joby deliver it?
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and…
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for…
Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with…
